MicroRNA Expression Profiles Predict Clinical Phenotypes and Prognosis in Chromophobe Renal Cell Carcinoma.

Yu-Zheng Ge,Hui Xin,Tian-Ze Lu,Zheng Xu,Peng Yu,You-Cai Zhao,Ming-Hao Li,Yan Zhao,Bing Zhong,Xiao Xu,Liu-Hua Zhou,Ran Wu,Lu-Wei Xu,Jian-Ping Wu,Wen-Cheng Li,Jia-Geng Zhu,Rui-Peng Jia
DOI: https://doi.org/10.1038/srep10328
IF: 4.6
2015-01-01
Scientific Reports
Abstract:Chromophobe renal cell carcinoma (chRCC) is the third most common subtype of kidney cancers. In the present study, we identified 58 treatment-naïve primary chRCC patients from The Cancer Genome Atlas dataset and analyzed the genome-wide microRNA (miRNA) expression profiles, with the aim to assess the relationship of miRNA expression with the progression and prognosis of chRCC. Overall, a total of 105 miRNAs were found to be differentially expressed between tumor and the adjacent normal tissues from 22 chRCC patients. In the unpaired condition (58 chRCC vs. 22 normal tissues), 77 (96.3%) samples were distinguished correctly by the signatures. In the progression-related profiles, 27 miRNAs were selected for pathologic T and 9 for lymph node involvement. In the survival analyses, the expression levels of mir-191, mir-19a, mir-210, and mir-425 were significantly associated with both recurrence-free survival (RFS) and overall survival, while mir-210 was proven as an independent prognostic factor in terms of RFS. In summary, miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC.
What problem does this paper attempt to address?